$ZSAN News
Last published 11mo ago
- 11mo agoZSANApproval of Nitroglycerin, Anda #218756FDA Approved DrugsApproval Date: 12/18/2025; Drug Name: Nitroglycerin, Anda #218756; Active Ingredients: NITROGLYCERIN; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 218756
- 1y agoZSANApproval of Diltiazem Hydrochloride, Nda #218038 (Type 5 - New Formulation or New Manufacturer)FDA Approved DrugsApproval Date: 02/21/2025; Drug Name: Diltiazem Hydrochloride, Nda #218038; Active Ingredients: DILTIAZEM HYDROCHLORIDE; Company: Hq Specialty Pharma Corp; Submission Status: Approval; Submission Classification: Type 5 - New Formulation or New Manufacturer; Application Number: 218038
- 2y agoZSANApproval of Estradiol, Anda #217863FDA Approved DrugsApproval Date: 07/12/2024; Drug Name: Estradiol, Anda #217863; Active Ingredients: ESTRADIOL; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 217863
- 2y agoZSANApproval of Estradiol, Anda #216160FDA Approved DrugsApproval Date: 04/22/2024; Drug Name: Estradiol, Anda #216160; Active Ingredients: ESTRADIOL; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 216160
- 3y agoZSANApproval of Tazarotene, Anda #213644FDA Approved DrugsApproval Date: 03/20/2023; Drug Name: Tazarotene, Anda #213644; Active Ingredients: TAZAROTENE; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 213644
- 4y agoZSANZosano Pharma Files Voluntary Petition for Relief Under Chapter 11GlobeNewswireFREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 ("Chapte
- 4y agoZSANEmergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma's Micro-Needle PatchGlobeNewswirePRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma's Micro-Needle Patch Emergex's COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials
- 4y agoZSANZosano Pharma Reports First Quarter 2022 Financial ResultsGlobeNewswireFREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information in
- 4y agoZSANZosano Pharma Provides Corporate UpdateGlobeNewswireFREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-
- 4y agoZSANZosano Pharma Announces Reverse Stock Split Effective TodayGlobeNewswireFREMONT, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company's common st
- 4y agoZSANZosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsGlobeNewswireFREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business upd
- 4y agoCANHEXOKGCVEON+1Thinking about buying stock in Kinross Gold, Hexo Corp, Canaan, Zosano Pharma, or VEON?PR NewswireNEW YORK, March 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KGC, HEXO, CAN, ZSAN, and VEON. To
- 4y agoCEIOXYPLTRZOM+1Thinking about buying stock in Camber Energy, Palantir Technologies, Zosano Pharma, Occidental Petroleum, or Zomedica?PR NewswireNEW YORK, Feb. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, PLTR, ZSAN, OXY, and ZOM. To
- 4y agoCSCWGOLDPBRSOFI+1Thinking about buying stock in Zosano Pharma, SoFi Technologies, Color Star Technology, Petroleo Brasileiro, or Barrick Gold?PR NewswireNEW YORK, Feb. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, SOFI, CSCW, PBR, and GOLD. T
- 4y agoZSANApproval of Clobetasol Propionate, Anda #211240FDA Approved DrugsApproval Date: 02/17/2022; Drug Name: Clobetasol Propionate, Anda #211240; Active Ingredients: CLOBETASOL PROPIONATE; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 211240
- 4y agoZSANApproval of Clindamycin Phosphate And Tretinoin, Anda #212845FDA Approved DrugsApproval Date: 02/10/2022; Drug Name: Clindamycin Phosphate And Tretinoin, Anda #212845; Active Ingredients: CLINDAMYCIN PHOSPHATE; TRETINOIN; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 212845
- 4y agoAMCBBDSNAPTEVA+1Thinking about buying stock in Zosano Pharma, Banco Bradesco, AMC Entertainment, Snap, or Teva Pharmaceutical?PR NewswireNEW YORK, Feb. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, BBD, AMC, SNAP, and TEVA. To
- 4y agoZSANZosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and WarrantsGlobeNewswireFREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each cons
- 4y agoZSANZosano Pharma Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswireFREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock
- 4y agoFAMIHOTHRELIX+1Thinking about buying stock in Farmmi, Zosano Pharma, Hoth Therapeutics, Reliance Global, or United States Steel?PR NewswireNEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, ZSAN, HOTH, RELI, and X. To
- 4y agoZSANZosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher DoseGlobeNewswireFREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, "Immunogenicity and Safety of
- 4y agoZSANZosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. YangGlobeNewswireFREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. "We are please
- 4y agoZSANZosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFREMONT, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano's common sto
- 4y agoGOEVPROGVIRYQ+1Thinking about buying stock in 17 Education & Technology, Progenity, Canoo, Vir Biotechnology, or Zosano Pharma?PR NewswireNEW YORK, Nov. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for YQ, PROG, GOEV, VIR, and ZSAN. To
- 4y agoZSANZosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch SystemGlobeNewswireFREMONT, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, util
- 5y agoZSANApproval of Dhivy, Nda #214869 (Type 5 - New Formulation or New Manufacturer)FDA Approved DrugsApproval Date: 11/12/2021; Drug Name: Dhivy, Nda #214869; Active Ingredients: CARBIDOPA;LEVODOPA; Company: Riverside Pharma Corp; Submission Status: Approval; Submission Classification: Type 5 - New Formulation or New Manufacturer; Application Number: 214869
- 5y agoZSANZosano Pharma Reports Third Quarter 2021 Financial ResultsGlobeNewswireFREMONT, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2021, as well as business highlights.
- 5y agoHEXONOKQSSOFI+1Thinking about buying stock in Zosano Pharma, SoFi Technologies, Quantumscape, Nokia, or Hexo?PR NewswireNEW YORK, Nov. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, SOFI, QS, NOK, and HEXO. To s
- 5y agoZSANApproval of Metronidazole, Anda #213648FDA Approved DrugsApproval Date: 10/14/2021; Drug Name: Metronidazole, Anda #213648; Active Ingredients: METRONIDAZOLE; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 213648
- 5y agoZSANZosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study ResultsGlobeNewswireFREMONT, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Adm
- 5y agoZSANZosano Pharma to Present at the H.C. Wainwright Virtual Global Investment ConferenceGlobeNewswireFREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H
- 5y agoZSANApproval of Clindamycin Phosphate, Anda #212842FDA Approved DrugsApproval Date: 08/13/2021; Drug Name: Clindamycin Phosphate, Anda #212842; Active Ingredients: CLINDAMYCIN PHOSPHATE; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 212842
- 5y agoZSANZosano Pharma Reports Second Quarter 2021 Financial ResultsGlobeNewswireFREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021, as well as business highlights.
- 5y agoZSANCrossover Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers - NCT04969497ClinicalTrials.govIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Cmax, Tmax
- 5y agoZSANZosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of MigraineGlobeNewswireFREMONT, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U
- 5y agoCLFJAGXLIZINOK+1Thinking about buying stock in Zosano Pharma, Lizhi, Nokia, Cleveland-Cliffs, or Jaguar Health?PR NewswireNEW YORK, May 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, LIZI, NOK, CLF, and JAGX. To
- 5y agoZSANZosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and PainGlobeNewswireFREMONT, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, "Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan
- 5y agoZSANZosano Appoints Industry Veteran, Kathy McGee, to its Board of DirectorsGlobeNewswireFREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directo
- 5y agoZSANZosano Pharma Reports First Quarter 2021 Financial ResultsGlobeNewswireFREMONT, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021, as well as business highlights. "
- 5y agoAMCNMTRPIRSXXII+1Thinking about buying stock in AMC Entertainment, 22nd Century Group, Zosano Pharma, Pieris Pharmaceuticals, or 9 Meters Biopharma?PR NewswireNEW YORK, April 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, XXII, ZSAN, PIRS, and NMTR.
- 5y agoZSANZosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDAGlobeNewswire– Company Establishes Agreement with Worldwide Clinical Trials to Conduct PK Study – – Anticipates initiating PK Study in June and Completion in Q3 2021 – FREMONT, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Cor
- 5y agoZSANApproval of Fluocinolone Acetonide, Anda #212762FDA Approved DrugsApproval Date: 04/02/2021; Drug Name: Fluocinolone Acetonide, Anda #212762; Active Ingredients: FLUOCINOLONE ACETONIDE; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 212762
- 5y agoZSANApproval of Fluocinolone Acetonide, Anda #212760FDA Approved DrugsApproval Date: 04/02/2021; Drug Name: Fluocinolone Acetonide, Anda #212760; Active Ingredients: FLUOCINOLONE ACETONIDE; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 212760
- 5y agoZSANApproval of Fluocinolone Acetonide, Anda #212761FDA Approved DrugsApproval Date: 04/02/2021; Drug Name: Fluocinolone Acetonide, Anda #212761; Active Ingredients: FLUOCINOLONE ACETONIDE; Company: Solaris Pharma Corp; Submission Status: Approval; Application Number: 212761
- 5y agoZSANZosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial ResultsGlobeNewswireFREMONT, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and...
- 5y agoZSANZosano Pharma to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswireFREMONT, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive...
- 5y agoZSANZosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDAGlobeNewswireFREMONT, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official...
- 5y agoZSANZosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of MigrainesGlobeNewswireReview of data from the ZOTRIP trial suggest that Qtrypta showed therapeutic gain at 30 minutes consistent with recently published criteria for evaluating early onset of actionAll Qtrypta patients who...
- 5y agoZSANZosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDAGlobeNewswireFREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company completed its Type A meeting...
- 5y agoZSANZosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug ApplicationGlobeNewswireFREMONT, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on December 30, 2020 the company...